MX2020002235A - Composicion para la estimulacion ovarica controlada. - Google Patents

Composicion para la estimulacion ovarica controlada.

Info

Publication number
MX2020002235A
MX2020002235A MX2020002235A MX2020002235A MX2020002235A MX 2020002235 A MX2020002235 A MX 2020002235A MX 2020002235 A MX2020002235 A MX 2020002235A MX 2020002235 A MX2020002235 A MX 2020002235A MX 2020002235 A MX2020002235 A MX 2020002235A
Authority
MX
Mexico
Prior art keywords
composition
ovarian stimulation
controlled ovarian
controlled
fsh
Prior art date
Application number
MX2020002235A
Other languages
English (en)
Spanish (es)
Inventor
Lisbeth Helmgaard
Bjarke Mirner Klein
Saez Joan - Carles Arce
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MX2020002235A publication Critical patent/MX2020002235A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pregnancy & Childbirth (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2020002235A 2017-09-01 2018-08-31 Composicion para la estimulacion ovarica controlada. MX2020002235A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17189119 2017-09-01
PCT/EP2018/073442 WO2019043143A1 (en) 2017-09-01 2018-08-31 COMPOSITION FOR CONTROLLED OVARIAN STIMULATION

Publications (1)

Publication Number Publication Date
MX2020002235A true MX2020002235A (es) 2020-07-20

Family

ID=59772482

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020002235A MX2020002235A (es) 2017-09-01 2018-08-31 Composicion para la estimulacion ovarica controlada.
MX2024009224A MX2024009224A (es) 2017-09-01 2020-02-27 Composicion para la estimulacion ovarica controlada.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024009224A MX2024009224A (es) 2017-09-01 2020-02-27 Composicion para la estimulacion ovarica controlada.

Country Status (32)

Country Link
US (2) US11744879B2 (enExample)
EP (3) EP4427806A3 (enExample)
JP (2) JP6856819B2 (enExample)
KR (2) KR20200045543A (enExample)
CN (2) CN111050787A (enExample)
AR (1) AR112541A1 (enExample)
AU (1) AU2018326556B2 (enExample)
BR (1) BR112020003379A2 (enExample)
CA (1) CA3073624A1 (enExample)
CL (1) CL2020000482A1 (enExample)
DK (2) DK3973982T3 (enExample)
EA (1) EA202090480A1 (enExample)
ES (2) ES2989511T3 (enExample)
FI (1) FI3973982T3 (enExample)
HR (2) HRP20211802T1 (enExample)
HU (2) HUE068024T2 (enExample)
IL (1) IL272763B2 (enExample)
JO (1) JOP20200034A1 (enExample)
LT (2) LT3675894T (enExample)
MA (2) MA56224B1 (enExample)
MD (2) MD3973982T2 (enExample)
MX (2) MX2020002235A (enExample)
MY (1) MY200791A (enExample)
PH (1) PH12020500404A1 (enExample)
PL (2) PL3675894T3 (enExample)
PT (2) PT3675894T (enExample)
RS (2) RS62810B1 (enExample)
SG (1) SG11202003840QA (enExample)
SI (2) SI3973982T1 (enExample)
TW (1) TWI749255B (enExample)
UA (1) UA126869C2 (enExample)
WO (1) WO2019043143A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
TW202237173A (zh) * 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1418107A (zh) * 2000-01-27 2003-05-14 应用研究系统Ars股份公司 用于治疗不孕症的卵泡刺激激素(fsh)的应用
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
CA2700335C (en) * 2007-09-21 2015-12-01 Pharmabrand S.A. Composition comprising mucilaginous polysaccharides derived from aloe barbadensis combined with liposomes, method for obtaining same and use thereof as a sun protector, an anti-acne agent, an epidermal regenerator and a moisturiser
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
EP2526111A2 (en) * 2010-01-21 2012-11-28 Ramot at Tel Aviv University, Ltd. Aloe-emodin derivatives and use thereof for the treatment of cancer
HRP20150968T4 (hr) 2010-09-29 2023-11-10 Ferring B.V. Pripravak za uporabu za liječenje neplodnosti
AR090095A1 (es) 2011-06-06 2014-10-22 Ferring Bv Preparacion farmaceutica que comprende hormona estimulante del foliculo recombinante
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
US20170035854A1 (en) * 2014-04-18 2017-02-09 Glycotope Gmbh Controlled ovarian hyperstimulation with improved recombinant human follicle-stimulating hormone
RU2723098C2 (ru) 2015-02-26 2020-06-08 Ферринг Б.В. Способы лечения бесплодия
ES2784625T3 (es) 2015-04-17 2020-09-29 Ferring Bv FSH para el tratamiento de la infertilidad
MX389908B (es) 2015-04-24 2025-03-20 Ferring Bv Metodo de produccion de gonadotrofina.
EP3313859B1 (en) 2015-06-26 2019-11-20 Ferring BV Methods of purification and/or viral inactivation
EP3787667B1 (en) 2018-04-30 2025-03-26 Ferring B.V. Composition for controlled ovarian stimulation
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法

Also Published As

Publication number Publication date
KR20250078595A (ko) 2025-06-02
IL272763B2 (en) 2024-02-01
JP6856819B2 (ja) 2021-04-14
EP3973982A1 (en) 2022-03-30
LT3675894T (lt) 2021-12-10
PL3675894T3 (pl) 2022-02-21
PT3675894T (pt) 2022-01-25
JP7373479B2 (ja) 2023-11-02
HRP20241171T1 (hr) 2024-11-22
AR112541A1 (es) 2019-11-06
JP2021046398A (ja) 2021-03-25
SI3675894T1 (sl) 2022-01-31
US11744879B2 (en) 2023-09-05
JOP20200034A1 (ar) 2020-02-13
ES2989511T3 (es) 2024-11-26
PT3973982T (pt) 2024-09-16
BR112020003379A2 (pt) 2020-08-25
MA56224A (fr) 2022-04-20
MA50034B1 (fr) 2022-02-28
UA126869C2 (uk) 2023-02-15
TW201919687A (zh) 2019-06-01
EP3675894A1 (en) 2020-07-08
SG11202003840QA (en) 2020-05-28
CL2020000482A1 (es) 2020-06-26
AU2018326556B2 (en) 2024-09-26
MY200791A (en) 2024-01-16
HUE056726T2 (hu) 2022-03-28
CN111050787A (zh) 2020-04-21
FI3973982T3 (fi) 2024-09-23
ES2904787T3 (es) 2022-04-06
MD3675894T2 (ro) 2022-03-31
EP3675894B1 (en) 2021-11-03
LT3973982T (lt) 2024-09-10
KR20200045543A (ko) 2020-05-04
US20200197493A1 (en) 2020-06-25
PH12020500404A1 (en) 2021-03-01
SI3973982T1 (sl) 2024-10-30
EA202090480A1 (ru) 2020-07-20
IL272763B1 (en) 2023-10-01
US20240024424A1 (en) 2024-01-25
HRP20211802T1 (hr) 2022-03-04
DK3973982T3 (da) 2024-09-23
IL272763A (en) 2020-04-30
HUE068024T2 (hu) 2024-12-28
MA56224B1 (fr) 2024-09-30
EP3973982B1 (en) 2024-07-31
PL3973982T3 (pl) 2024-11-04
JP2020528071A (ja) 2020-09-17
MD3973982T2 (ro) 2024-11-30
CA3073624A1 (en) 2019-03-07
EP4427806A3 (en) 2024-10-09
MX2024009224A (es) 2024-08-06
EP4427806A2 (en) 2024-09-11
DK3675894T3 (da) 2022-01-24
AU2018326556A1 (en) 2020-03-05
RS65945B1 (sr) 2024-10-31
WO2019043143A1 (en) 2019-03-07
TWI749255B (zh) 2021-12-11
CN120617484A (zh) 2025-09-12
RS62810B1 (sr) 2022-02-28
MA50034A (fr) 2021-05-12

Similar Documents

Publication Publication Date Title
PH12020551923A1 (en) Methods and compositions for treating cancer
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
MX2024008826A (es) Composicion para la estimulacion ovarica controlada.
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
EP4603508A3 (en) Anti-frizzled antibodies and methods of use
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
PH12021550122A1 (en) Solubilized apyrases, methods and use
PH12017501300A1 (en) Novel iodophor composition and methods of use
MY199876A (en) Anti-pacap antibody
MX379201B (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
PH12020500079A1 (en) Novel substituted xanthine derivates
EP3524257A4 (en) USE OF POLYPEPTIDE IN CONNECTION WITH EXCITATIVE NERVOUS INJURY IN THE PREVENTION, REDUCTION OR TREATMENT OF PAIN
MX2020001632A (es) Composiciones que comprenden cepas bacterianas.
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
MX2021006102A (es) Suministro mejorado de agentes grandes.
PH12020500404A1 (en) Composition for controlled ovarian stimulation
MX2018002921A (es) Composicion de hormona foliculo-estimulante mamifera con estabilidad incrementada.
MX2024010826A (es) Metodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
MX2020011738A (es) Uso de calcifediol en pacientes de cirugia bariatrica.
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
MA53909B1 (fr) Compositions et méthodes de stimulation ovarienne contrôlée
PH12019502145A1 (en) Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient
MX2019009293A (es) Compuestos, composiciones y usos de los mismos para la mejoria de trastornos oseos.
EP4371613A3 (en) Compounds for use in the treatment of ocular pain